Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $45.8100 (-2.22%) ($45.8100 - $46.7200) on Wed. Feb. 17, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.38% (three month average) | RSI | 53 | Latest Price | $45.8100(-2.22%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -2.3% a day on average for past five trading days. | Weekly Trend | TGTX declines -0.7% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(67%) ARKG(63%) ARKK(59%) IBB(58%) IWO(58%) | Factors Impacting TGTX price | TGTX will decline at least -3.19% in a week (0% probabilities). VIXM(-42%) VXX(-36%) UUP(-18%) UNG(-3%) TBT(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.19% (StdDev 6.38%) | Hourly BBV | -1.1 () | Intraday Trend | 0% | | | |
|
Resistance Level | $49.07 | 5 Day Moving Average | $47.79(-4.14%) | 10 Day Moving Average | $49.3(-7.08%) | 20 Day Moving Average | $49.07(-6.64%) | To recent high | -16.3% | To recent low | 68.5% | Market Cap | $5.802b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |